226 related articles for article (PubMed ID: 16127532)
1. Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure.
Albuali WH; Singh RN; Fraser DD; Scott LA; Kornecki A
Saudi Med J; 2005 Aug; 26(8):1289-92. PubMed ID: 16127532
[TBL] [Abstract][Full Text] [Related]
2. Drotrecogin alfa (activated) in an infant with gram-negative septic shock.
Sajan I; Da-Silva SS; Dellinger RP
J Intensive Care Med; 2004; 19(1):51-5. PubMed ID: 15035755
[TBL] [Abstract][Full Text] [Related]
3. Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*.
Dalton HJ; Carcillo JA; Woodward DB; Short MA; Williams MD
Pediatr Crit Care Med; 2012 Nov; 13(6):639-45. PubMed ID: 22791090
[TBL] [Abstract][Full Text] [Related]
4. Use of drotrecogin alfa (activated) in two patients with severe sepsis.
Mikaszewska-Sokolewicz M; Nierebińska M; Mayzner-Zawadzka E
Med Sci Monit; 2003 Aug; 9(8):CS80-7. PubMed ID: 12942037
[TBL] [Abstract][Full Text] [Related]
5. Drotrecogin alfa (activated) in severe falciparum malaria.
Kendrick BJ; Gray AG; Pickworth A; Watters MP
Anaesthesia; 2006 Sep; 61(9):899-902. PubMed ID: 16922759
[TBL] [Abstract][Full Text] [Related]
6. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
[TBL] [Abstract][Full Text] [Related]
7. Readministration of drotrecogin alfa (activated) in an adult with severe sepsis.
Scipione MR; Nogid B; Davanos E; DiGregorio RV
Am J Health Syst Pharm; 2011 Sep; 68(18):1711-5. PubMed ID: 21880886
[TBL] [Abstract][Full Text] [Related]
8. [Clinical approach to the identification of patients suffering from severe sepsis with several organ failures for the administration of drotrecogin alfa (activated): from the PROWESS study to clinical practice].
Dhainaut JF; Payen DM; Bernardin G; Gérard JL; Martin C; Perrotin D; Regnier B
Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():53-64. PubMed ID: 15359946
[No Abstract] [Full Text] [Related]
9. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.
Betancourt M; McKinnon PS; Massanari RM; Kanji S; Bach D; Devlin JW
Pharmacoeconomics; 2003; 21(18):1331-40. PubMed ID: 14750900
[TBL] [Abstract][Full Text] [Related]
10. Drotrecogin alpha (activated) in neonatal septic shock.
Frommhold D; Birle A; Linderkamp O; Zilow E; Pöschl J
Scand J Infect Dis; 2005; 37(4):306-8. PubMed ID: 15804668
[TBL] [Abstract][Full Text] [Related]
11. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
McCoy C; Matthews SJ
Clin Ther; 2003 Feb; 25(2):396-421. PubMed ID: 12749504
[TBL] [Abstract][Full Text] [Related]
12. Is worsening multiple organ failure the cause of death in patients with severe sepsis?
Vincent JL; Nelson DR; Williams MD
Crit Care Med; 2011 May; 39(5):1050-5. PubMed ID: 21317650
[TBL] [Abstract][Full Text] [Related]
13. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
[TBL] [Abstract][Full Text] [Related]
14. The use of drotrecogin alfa in severe falciparum malaria.
Robak O; Bojic A; Locker GJ; Laczika K; Ramharter M; Staudinger T
Anaesth Intensive Care; 2010 Jul; 38(4):751-4. PubMed ID: 20715743
[TBL] [Abstract][Full Text] [Related]
15. Drotrecogin alfa (activated) for the treatment of severe sepsis and septic shock.
Rice TW; Bernard GR
Am J Med Sci; 2004 Oct; 328(4):205-14. PubMed ID: 15486535
[TBL] [Abstract][Full Text] [Related]
16. A novel use for drotrecogin alfa (activated): successful treatment of septic shock associated with coccidioidomycosis.
Crum NF; Groff HL; Parrish JS; Ring W
Clin Infect Dis; 2004 Dec; 39(11):e122-3. PubMed ID: 15578351
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
[TBL] [Abstract][Full Text] [Related]
18. Clinical response to unintentionally rapid infusion of drotrecogin alfa (activated).
Urban TM; Mitchell GA; Wellborn-Kim JJ; Terneus WF; Callahan CM; Mendes J; Webber SL
Am J Health Syst Pharm; 2010 Jul; 67(14):1174-7. PubMed ID: 20592322
[TBL] [Abstract][Full Text] [Related]
19. Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C.
Pastores SM; Papadopoulos E; van den Brink M; Alicea M; Halpern NA
Bone Marrow Transplant; 2002 Jul; 30(2):131-4. PubMed ID: 12132053
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome.
Barie PS; Hydo LJ; Shou J; Eachempati SR
Surg Infect (Larchmt); 2011 Dec; 12(6):443-9. PubMed ID: 22185191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
